| Terminalia arjuna in coronary artery disease: ethnopharmacology, pre-clinical, clinical & safety evaluation D Kapoor, R Vijayvergiya, V Dhawan Journal of ethnopharmacology 155 (2), 1029-1045, 2014 | 98 | 2014 |
| Levels of Interleukin‐18 and Endothelin‐1 in Children with Henoch‐Schönlein Purpura: A Study from N orthern I ndia N Mahajan, D Kapoor, D Bisht, S Singh, RW Minz, V Dhawan Pediatric Dermatology 30 (6), 695-699, 2013 | 22 | 2013 |
| Conventional therapies fail to target inflammation and immune imbalance in subjects with stable coronary artery disease: a system-based approach D Kapoor, D Trikha, R Vijayvergiya, D Kaul, V Dhawan Atherosclerosis 237 (2), 623-631, 2014 | 20 | 2014 |
| Short-Term Adjuvant Therapy with Terminalia arjuna Attenuates Ongoing Inflammation and Immune Imbalance in Patients with Stable Coronary Artery Disease: In … D Kapoor, D Trikha, R Vijayvergiya, KK Parashar, D Kaul, V Dhawan Journal of Cardiovascular Translational Research 8, 173-186, 2015 | 19 | 2015 |
| Analysis of traditional and emerging risk factors in premenopausal women with coronary artery disease: A pilot-scale study from North India R Vijayvergiya, D Kapoor, A Aggarwal, S Sangwan, V Suri, V Dhawan Molecular and Cellular Biochemistry 432, 67-78, 2017 | 6 | 2017 |
| Correlation between soluble receptor for advanced glycation end products levels and coronary artery disease in postmenopausal nondiabetic women DV Ghosh S, Kapoor D, Vijayvergiya R, Sangwan S, Wangkheimayum S, Mehta S World Journal of Cardiology 13 (5), 130-143, 2021 | 2 | 2021 |
| Modulatory effects of Terminella arjuna in medicated stable patients of coronary artery disease Kapoor D, Trikha D, Vijayvergiya R, Dhawan V Translation Medicine 3 (2), 125, 2013 | | 2013 |
Veena DhawanPGIMER, Chandigarh, IndiaVerifierad e-postadress på pgimer.edu.in
